MarketInOut Stock Screener Log In | Sign Up

Exelixis Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/17/2026 15:44
Exelixis Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization16,500 mln
Float236 mln
Earnings Date02/09/2027

EPS

3.34
Solid

P / E

20.46
Premium valuation

Piotroski F-Score

7 / 9
Strong

Beneish M-Score

-3.05
Reliable

1-Year Forecast

61.57
Limited downside

Relative Strength

37 / 100
Underperforming

Business Description

Exelixis is a US-based cancer treatment company that develops and sells medicines for hard-to-treat cancers, with its core products built around cabozantinib, a compound that targets multiple proteins involved in tumor growth. Its approved treatments address cancers including advanced kidney cancer, thyroid cancer, and melanoma, while a broader pipeline of experimental therapies is currently in development. Founded in 1994 and based in Alameda, California, the company works alongside a wide network of pharmaceutical partners to advance its research and expand the reach of its treatments.

Key Fundamentals

EPS3.34
P/E20.46
ROE44.54
RPS9.77
ROIC53.05
ROA33.26
EBITDA, mln1,094
EV / EBITDA15.05
EV / EBIT15.45
Revenue, mln2,497
EV / Revenue6.59

Quote Details

Last 68.24
Change 1.14 (1.7%)
Open 66.75
Volume 1,438,573
Turnover 98,168,216
Average Volume 2,644,228

Financial Ratios

Pre-Tax Profit Margin43
Leverage Ratio1.37
Current Ratio3.21
Price / Book9.26
Price / Tangible Book9.58
Price / Cash Flow14.22
Price / Free Cash Flow15.83
Debt / Equity0.09
Price / Sales7.34
PEG Ratio0.46

Financial Strength

Altman Z-Score17.86
Piotroski F-Score 7 / 9
Beneish M-Score-3.05
Price to Intrinsic Value1.87
Price to Lynch Fair Value0.83
Price to Graham Number2.97
1-Year Target Price61.57
Shiller PE Ratio45.90
Short Ratio10.77
Short % of Float14.42

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -3.32% 45 / 100   
1 Month 8.87% 91 / 100   
2 Months 35.45% 98 / 100   
6 Months 40.21% 95 / 100   
1 Year 63.84% 95 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog